Table 2.

ANXA5, CRKI/II and RAC1 overexpression was correlated with HCC progression and metastasis

Parameters	Total	ANXA5				P	CRKI/II				P	RAC1				P
		−	+	++	+++		−	+	++	+++		−	+	++	+++
Age, years						0.219					0.795					0.261
< 60	37	6	11	13	7		3	5	27	2		1	1	21	14
≥ 60	9	1	1	5	2		0	2	6	1		0	0	4	5
Gender						0.499					0.029					0.482
Male	35	5	9	15	6		2	2	29	2		1	0	17	17
Female	11	2	3	3	3		1	5	4	1		0	1	8	2
Edmondson grade						0.219					0.165					0.889
I–II	22	1	8	9	4		3	4	14	1		1	0	11	10
III–IV	19	6	4	6	3		0	3	14	2		0	0	10	9
TNM stage						0.015					0.117					0.011
I–II	23	4	10	7	2		3	4	15	1		1	0	17	5
III–IV	23	3	2	11	7		0	3	18	2		0	1	8	14
AFU, U/mL						0.814					0.991					0.345
≤20	17	0	6	9	2		1	2	14	0		1	0	11	5
20–400	9	3	0	3	3		1	1	6	1		0	0	4	5
>400	19	3	6	6	4		1	4	12	2		0	1	10	8
HBsAg						0.38					0.479					0.420
Negative	9	2	4	1	2		0	3	6	0		0	0	7	2
Positive	33	5	8	14	6		3	4	23	3		1	0	18	14
HBsAb						0.251					0.663					0.53
Negative	37	7	9	14	7		3	6	25	3		1	0	24	12
Positive	3	0	3	0	0		0	0	3	0		0	0	1	2
HBeAb						0.333					0.794					0.472
Negative	8	2	1	3	2		0	2	5	1		0	1	5	2
Positive	33	4	11	13	5		3	5	23	2		1	0	20	12
HBcAb						0.261					0.622					0.308
Negative	5	1	0	2	2		0	1	4	0		0	0	2	3
Positive	37	6	12	13	6		3	6	25	3		1	1	23	12